Artemisinin Systematic (IUPAC) name (3R,5aS,6R,8aS,9R,12S,12aR)-
Clinical data Pregnancy cat. ? Legal status ? Routes Oral Identifiers CAS number ATC code P01 PubChem ChemSpider UNII KEGG ChEBI ChEMBL Synonyms Artemisinine, Qinghaosu Chemical data Formula C15H22O5 Mol. mass 282.332 g/mol SMILES & Physical data Density 1.24 ± 0.1 g/cm³ Melt. point 152–157 °C (306–315 °F) (what is this?)
Artemisinin ( //), also known as Qinghaosu (Chinese: 青蒿素) , and its derivatives are a group of drugs that possess the most rapid action of all current drugs against falciparum malaria. Treatments containing an artemisinin derivative (artemisinin-combination therapies, ACTs) are now standard treatment worldwide for falciparum malaria. The starting compound artemisinin is isolated from the plant Artemisia annua, a herb described in Chinese traditional medicine.
Chemically, artemisinin is a sesquiterpene lactone containing an unusual peroxide bridge. It is believed that this peroxide is responsible for the drug's mechanism of action. No other natural compound with such a peroxide bridge is known.
Use of the drug by itself as a monotherapy is explicitly discouraged by the World Health Organization as there have been signs that malarial parasites are developing resistance to the drug. Therapies that combine artemisinin with some other anti-malarial drug are the preferred treatment for malaria and are both effective and well tolerated in patients. The drug is also increasingly being used in vivax malaria as well as being a topic of research in cancer treatment.
- 1 History
- 2 Artemisinin derivatives
- 3 Indications
- 4 Resistance
- 5 Adverse effects
- 6 Mechanism of action
- 7 Dosing
- 8 Production and price
- 9 Synthesis
- 10 References
- 11 External links
Artemisia has been used by Chinese herbalists for more than a thousand years in the treatment of many illnesses, such as skin diseases and malaria. The earliest record dates back to 200 BC, in the "Fifty-two Prescriptions" unearthed from the Mawangdui Han Dynasty Tombs. Its antimalarial application was first described, in Zhouhou Beiji Fang ("The Handbook of Prescriptions for Emergencies", Chinese: 肘后备急方), edited in the middle of the fourth century by Ge Hong. In that book, 43 malaria treatment methods were recorded.
In the 1960s a research program, under the name Project 523, was set up by the Chinese army to find an adequate treatment for malaria. In 1972, in the course of this research, Dr. Tu Youyou discovered artemisinin in the leaves of Artemisia annua (annual wormwood). The drug is named Qinghaosu (Chinese: 青蒿素) in Chinese. It was one of many candidates then tested by Chinese scientists from a list of nearly 5000 traditional Chinese medicines for treating malaria. It was the only one that was effective, but it was found that it cleared malaria parasites from their bodies faster than any other drug in history. Artemisia annua is a common herb and has been found in many parts of the world, including along the Potomac River, in Washington, D.C. Images of the original scientific papers are available online and a book, Zhang Jianfang, "Late Report – Record of Project 523 and the Research and Development of Qinghaosu", Yangcheng Evening News Publisher 2007(張劍方. 遲到的報告五二三項目與青蒿素研發紀實. 羊城晚報出版社, 2007), was published in 2006, which records the history of the discovery.
It remained largely unknown to the rest of the world for about seven years, until results were published in the Chinese Medical Journal in 1979. The report was met with skepticism at first, partly because the chemical structure of artemisinin, particularly the peroxide, appeared to be too unstable to be a viable drug.
For many years after the discovery, access to the purified drug and the plant it was extracted from were restricted by the Chinese government. It was not until the late 1970s and early 80s that news of the discovery reached scientists outside China. The World Health Organisation (WHO) tried to contact Chinese scientists and officials to find out more, but drew a blank. Dr Ying Lee, one of the scientists involved in the research into artemisinin, said the Chinese distrusted the West. The Chinese suspected the West just wanted to exploit the drug and sell it around the world slightly altered and repatented. The fact that there were several Americans on the WHO's steering board on malaria and that some were from the military did not help clear the distrust. It can be noted Americans had just invested a lot into mefloquine, an analogue of quinine.
In 2006, after artemisinin had become the treatment of choice for malaria, the WHO called for an immediate halt to single-drug artemisinin preparations in favor of medications that combine artemisinin with another malaria drug, in order to reduce the risk of parasites developing resistance.
- Artesunate (water-soluble: for oral, rectal, intramuscular, or intravenous use)
- Artemether (lipid-soluble: for oral, rectal or intramuscular use)
- Artelinic acid
There are also simplified analogs in preclinical research.
A synthetic compound with a similar trioxolane structure (ring containing three oxygen atoms) named arterolane showed promise in in vitro testing. Phase II testing in patients with malaria was not as successful as hoped, but the manufacturer decided to start Phase III testing anyway. A combination with piperaquine is also in development.
Artemisinins can be used alone, but this leads to a high rate of recrudescence (return of parasites) and other drugs are required to clear the body of all parasites and prevent recurrence. The World Health Organization is pressuring manufacturers to stop making the uncompounded drug available to the medical community at large, aware of the catastrophe that would result if the malaria parasite developed resistance to artemisinins.
The World Health Organisation has recommended that artemisinin combination therapies (ACT) be first-line therapy for P. falciparum malaria worldwide. Combinations are effective because the artemisinin component kills the majority of parasites at the start of the treatment while the more slowly eliminated partner drug clears the remaining parasites.
Several fixed-dose ACTs are now available containing an artemisinin component and a partner drug which has a long half-life, such as mefloquine (ASMQ), lumefantrine (Coartem), amodiaquine (ASAQ), piperaquine (Duo-Cotecxin) and pyronaridine (Pyramax). Increasingly these combinations are being made to GMP standard. A separate issue concerns the quality of some artemisinin-containing products being sold in Africa and South-East Asia.
Artemisinins are not used for malaria prophylaxis (prevention) because of the extremely short activity (half-life) of the drug. To be effective, it would have to be administered multiple times each day.
Artesunate administered by intravenous or intramuscular injection has proven superior to quinine in large, randomised controlled trials in both adults  and children. Combining all trials comparing these two drugs, artesunate is associated with a mortality rate that is approximately 30% lower than that of quinine. Reasons for this difference include reduced incidence of hypoglycaemia, easier administration and more rapid action against circulating and sequestered parasites.
Artemisinin is undergoing early research and testing for the treatment of cancer, primarily by researchers at the University of Washington. Chinese scientists have shown artemisinin has significant anticancer effects against human hepatoma cells. Artemisinin has a peroxide lactone group in its structure, and it is thought that when the peroxide comes into contact with high iron concentrations (common in cancerous cells), the molecule becomes unstable and releases reactive oxygen species. It has been shown to reduce angiogenesis and the expression of vascular endothelial growth factor in some tissue cultures. Recent pharmacological evidence demonstrates that the artemisinin-derivative dihydroartemisinin targets human metastatic melanoma cells with induction of NOXA (Phorbol-12-myristate-13-acetate-induced protein 1)-dependent mitochondrial apoptosis that occurs downstream of iron-dependent generation of cytotoxic oxidative stress.
Serendipitous discovery was made in China while searching for novel anthelmintics for schistosomiasis. Artemisinin was effective against schistosomes, the human blood flukes, which are the second most prevalent parasitic infections, after malaria. Artemisinin and its derivatives are all potent anthelmintics. Artemisinins were later found to possess a broad spectrum of activity against a wide range of trematodes including Schistosoma japonicum, S. mansoni, S. haematobium, Clonorchis sinensis, Fasciola hepatica and Opisthorchis viverrini. Clinical trials were also successfully conducted in Africa among patients with schistosomiasis. A randomized, double-blind placebo-controlled trial also revealed the efficacy against schistosome infection in Côte d'Ivoire and China.
A 2008 study suggests a consensus among researchers that artemisinin is losing its potency in Cambodia and increased efforts are required to prevent drug-resistant malaria from spreading across the globe. These findings were subsequently supported by a detailed study from Western Cambodia.
In April 2011 the World Health Organization stated that resistance to the most effective anti-malarial drug, artemisinin, could unravel national (India) malaria control programs, which have achieved significant progress in the last decade. WHO advocates the rational use of anti-malarial drugs and acknowledges the crucial role of community health workers in reducing malaria in the region.
Artemisinins are generally well tolerated at the doses used to treat malaria. The side effects from the artemisinin class of medications are similar to the symptoms of malaria: nausea, vomiting, anorexia, and dizziness. Mild blood abnormalities have also been noted. A rare but serious adverse effect is allergic reaction. One case of significant liver inflammation has been reported in association with prolonged use of a relatively high-dose of artemisinin for an unclear reason (the patient did not have malaria). The drugs that are used in combination therapies can contribute to the adverse effects that are experienced by those undergoing treatment. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives tend to be higher.
Mechanism of action
There is no consensus regarding the mechanism through which artemisinin derivatives kill the parasites. Their site of action within the parasite also remains controversial.
When the parasite that causes malaria infects a red blood cell, it consumes hemoglobin within its digestive vacuole, liberating free heme, an iron-porphyrin complex. According to one theory about the action of artemisinin, the iron of the heme reduces the peroxide bond in artemisinin, generating high-valent iron-oxo species and resulting in a cascade of reactions that produce reactive oxygen radicals which damage the parasite and lead to its death.
Numerous studies have investigated the type of damage that oxygen radicals may induce. For example, Pandey et al. have observed inhibition of digestive vacuole cysteine protease activity of malarial parasite by artemisinin. These observations were supported by ex vivo experiments showing accumulation of hemoglobin in the parasites treated with artemisinin and inhibition of hemozoin formation by malaria parasites. Electron microscopic evidence linking artemisinin action to the parasite's digestive vacuole has been obtained showing that the digestive vacuole membrane suffers damage soon after parasites are exposed to artemisinin. This would also be consistent with data showing that the digestive vacuole is already established by the mid-ring stage of the parasite's blood cycle, a stage that is sensitive to artemisinins but not other antimalarials.
A commonly cited theory that the parasite's SERCA pump (PfATP6) is a key target of artemisinins now appears highly questionable. Artemisinins do not inhibit this protein when it is expressed in yeast and transfection studies show no significant effect of PfATP6 genotype on artemisinin phenotype. Although a single field study identified a mutation in PfATP6 that was associated with resistance to artemether, this mutation has not achieved a meaningful prevalence in any location and the phenotypic association is not replicated elsewhere. There is no role for PfSERCA in the artemisinin resistance that appears to be emerging in Cambodia.
A 2005 study investigating the mode of action of artemisinin using a yeast model demonstrated that the drug acts on the electron transport chain, generates local reactive oxygen species, and causes the depolarization of the mitochondrial membrane.
Artemisinin and its derivatives have half-lives in the order of a few hours and therefore require at least daily dosing, usually for three days. For example the WHO approved adult dose of co-artemether (artemether-lumefantrine) is 4 tablets at 0, 8, 24, 36, 48 and 60 hours (six doses). This regimen has been proven to be superior to regimens based on amodiaquine.
Artemisinin is not soluble in water and therefore Artemisia annua tea was postulated not to contain pharmacologically significant amounts of artemesinin. However, this conclusion was rebuked by several experts who stated that hot water (85 oC), and not boiling water, should be used to prepare the tea. Although Artemisia tea is not recommended as a substitute for the ACT (artemisinin combination therapies) more clinical studies on artemisia tea preparation have been suggested.
Production and price
Artemisinin is the only high-volume drug that continues to be produced from a plant-based source. China and Vietnam provide 70% and East Africa 20% of the raw material. Seedlings are grown in nurseries and then transplanted into fields. It takes about 8 months for them to reach full size. The plants are harvested, the leaves are dried and sent to facilities where the artemisinin is extracted using solvent, typically hexane. The market price for artemisinin has fluctuated widely, between $120 and $1200 per kilogram from 2005 to 2008.
After negotiation with the WHO, Novartis and Sanofi-Aventis provide ACT (artemisinin combination therapy) drugs at cost on a non-profit basis; however, these drugs are still more expensive than other malaria treatments.
Using seed supplied by Action for Natural Medicine (ANAMED), the World Agroforestry Centre (ICRAF) has developed a hybrid, dubbed A3, which can grow to a height of 3 m and which produces 20 times more artemisinin than wild varieties. In northwestern Mozambique, ICRAF is working together with a medical organisation, Médecins sans frontières, ANAMED and the Ministry of Agriculture and Rural Development to train farmers on how to grow the shrub from cuttings, and to harvest and dry the leaves to make artemisia tea.
A research group from the Philippines have published a work on the extraction of artemisinin from its plant source, Artemisia annua. They produced a synthetic polymer that was imprinted with artemisinin and showed a selective recognition to said compound.
Biosynthesis in A. annua
The biosynthesis of artemisinin is expected to involve the mevalonate pathway (MVA) and the cyclization of FDP (farnesyl diphosphate). Although it is not clear whether the DXP (deoxyxylulose phosphate)pathway can also contribute 5-carbon precursors (IPP or/and DMAPP), as occurs in other sesquiterpene biosynthetic systems. The routes from artemisinic alcohol to artemisinin remain controversial and they differ mainly in when the reduction step takes place. Both routes suggested dihydroartemisinic acid as the final precursor to artemisinin. Dihydroartemisinic acid then undergoes photo-oxidation to produce dihydroartemisinic acid hydroperoxide. Ring expansion by the cleavage of hydroperoxide and a second oxygen-mediated hydroperoxidation furnish the biosynthesis of artemisinin.
Figure 1. Biosynthesis of Artemisinin.
The total synthesis of artemisinin, while expensive, can be performed using basic organic reagents. In 1982, G. Schmid and W. Hofheinz published a paper showing the complete synthesis of artemisinin. Their starting material was (-)-Isopulegol (2) which as converted to methoxymethyl ether (3). The ether was hydroborated and then underwent oxidative workup to give (4). The primary hydroxyl group was then benzylated and the methoxymethyl ether was cleaved resulting in (5) which would be oxidized to (6). Next, the compound was protonated and treated with (E)-(3-iodo-1-methyl-1-propenyl)-trimethylsilane to give (7). This resulting ketone was reacted with lithium methoxy(trimethylsily)methylide to obtain two diastereomeric alcohols, (8a) and (8b). 8a was then debenzylated using (Li, NH3) to give lactone (9). The vinylsilane was then oxidized to ketone (10). The ketone was then reacted with fluoride ion that caused it to undergo desilylation, enol ether formation and carboxylic acid formation to give (11). An introduction of a hydroperoxide function at C(3) of 11 gives rise to (12). Finally, this underwent photooxygenation and then treated with acid to produce artemisinin.
Synthesis in engineered organisms
In 2006 a team from UC Berkeley reported that they had engineered Saccharomyces cerevisiae yeast to produce the precursor artemisinic acid. The synthesized artemisinic acid can then be transported out, purified and chemically converted into artemisinin that they claim will cost roughly 0.25 cents per dose. In this effort of synthetic biology, a modified mevalonate pathway was used and the yeast were engineered to express the enzyme amorphadiene synthase and a cytochrome P450 monooxygenase (CYP71AV1), both from A. annua. A three-step oxidation of amorpha-4,11-diene gives the resulting artemisinic acid. Amyris Inc. collaborated with UC Berkeley and the Institute for One World Health to further develop this technology. The collaboration, known as the Artemisinin Project, is supported by funding from the Bill & Melinda Gates Foundation, and aims to create a source of non-seasonal, high-quality and affordable artemisinin to supplement the botanical supply, with the objective of making ACTs more accessible. The technology is based on inventions licensed from UC Berkeley and the National Research Council (NRC) Plant Biotechnology Institute of Canada. In 2011, OneWorld Health announced that the project has entered the "production and distribution" phase. Integration of semisynthetic artemisinin into the supply chain is planned for 2012.
According to the WHO World Malaria Report 2010, semisynthetic artemisinin from yeast will not become available on the market until 2012 at which time it will supplement botanical sources.
- ^ White NJ (July 1997). "Assessment of the pharmacodynamic properties of antimalarial drugs in vivo". Antimicrob. Agents Chemother. 41 (7): 1413–22. PMC 163932. PMID 9210658. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=163932.
- ^ a b "Artemisinin and a new generation of antimalarial drugs". Education in Chemistry. July 2006. http://www.rsc.org/Education/EiC/issues/2006July/Artemisinin.asp.
- ^ Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN (June 2010). "Artemisinin combination therapy for vivax malaria". Lancet Infect Dis 10 (6): 405–16. doi:10.1016/S1473-3099(10)70079-7. PMID 20510281.
- ^ ChinaVitae: Tu Youyou
- ^ a b c Miller L.H. and Su X. (September 16, 2011). "Artemisinin: discovery from the Chinese herbal garden.". Cell (CAMBRIDGE, MA 02139, USA: Cell Press) 146 (6): 855–858. doi:10.1016/j.cell.2011.08.024. ISSN 0092-8674. PMID 21907397. http://www.sciencedirect.com/science/article/pii/S0092867411009500.
- ^ Qinghaosu Project
- ^ ycwb.com
- ^ "Antimalaria studies on Qinghaosu". Chin. Med. J. 92 (12): 811–6. December 1979. PMID 117984.
- ^ "WHO calls for an immediate halt to provision of single-drug artemisinin malaria pills". WHO. 19 January 2006. http://www.who.int/mediacentre/news/releases/2006/pr02/en/.
- ^ Elizabeth Weise, "'America's Nobel' awarded to Chinese scientist", USA Today, 12 September 2011, accessed September 12, 2011.
- ^ Gary H. Posner; Michael H. Parker; Northrop, John; Elias, Jeffrey S.; Ploypradith, Poonsakdi; Xie, Suji; Shapiro, Theresa A. (1999). "Orally Active, Hydrolytically Stable, Semisynthetic, Antimalarial Trioxanes in the Artemisinin Family". J. Med. Chem. 42 (2): 300–304. doi:10.1021/jm980529v. PMID 9925735.
- ^ Vennerstrom JL, Arbe-Barnes S, Brun R, et al. (August 2004). "Identification of an antimalarial synthetic trioxolane drug development candidate". Nature 430 (7002): 900–4. doi:10.1038/nature02779. PMID 15318224.
- ^ C.H. Unnikrishnan (September 21, 2007). "Blow to Ranbaxy drug research plans". livemint.com. http://www.livemint.com/2007/09/21011423/Blow-to-Ranbaxy-drugresearch.html.
- ^ Rehwagen C (May 2006). "WHO ultimatum on artemisinin monotherapy is showing results". BMJ 332 (7551): 1176. doi:10.1136/bmj.332.7551.1176-b. PMC 1463909. PMID 16709988. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1463909.
- ^ Guidelines for the Treatment of Malaria.. Geneva: World Health Organization. 2006. ISBN 92-4-154694-8.
- ^ White NJ (April 2004). "Antimalarial drug resistance". J. Clin. Invest. 113 (8): 1084–92. doi:10.1172/JCI21682. PMC 385418. PMID 15085184. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=385418.
- ^ Krudsood S, Looareesuwan S, Tangpukdee N, et al. (June 2010). "New fixed dose artesunate/mefloquine for treating multidrug resistant Plasmodium falciparum in adults — a comparative phase IIb safety and pharmacokinetic study with standard dose non-fixed artesunate plus mefloquine". Antimicrob Agents Chemother 54 (9): 3730–7. doi:10.1128/AAC.01187-09. PMC 2935027. PMID 20547795. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2935027.
- ^ "Malaria drugs recalled in Kenya". BBC News. 17 August 2007. http://news.bbc.co.uk/2/hi/africa/6951586.stm.
- ^ Newton P, Proux S, Green M, et al. (June 2001). "Fake artesunate in southeast Asia". Lancet 357 (9272): 1948–50. doi:10.1016/S0140-6736(00)05085-6. PMID 11425421.
- ^ Dondorp A, Nosten F, Stepniewska K, Day N, White N (2005). "Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial". Lancet 366 (9487): 717–25. doi:10.1016/S0140-6736(05)67176-0. PMID 16125588.
- ^ a b Dondorp AM, Fanello CI, Hendriksen IC, et al. (November 2010). "Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial". Lancet 376 (9753): 1647–57. doi:10.1016/S0140-6736(10)61924-1. PMC 3033534. PMID 21062666. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3033534.
- ^ University of Washington: News
- ^ University of Washington: Artemisinin
- ^ Hou J, Wang D, Zhang R, Wang H (2008). "Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action". Clin Cancer Res 14 (7): 5519–5530. doi:10.1158/1078-0432.CCR-08-0197. PMID 18765544. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=18765544.
- ^ Cabello CM, Lamore SD, Bair WB 3rd, Qiao S, Azimian S, Lesson JL, Wondrak GT (2011). "The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis". Invest. New Drugs. doi:10.1007/s10637-011-9676-7. PMID 21547369. http://www.ncbi.nlm.nih.gov/pubmed/21547369.
- ^ Xiao SH. (2005). "Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins.". Acta Trop. 96 (2-3): 153–167. doi:10.1016/j.actatropica.2005.07.010. PMID 16112072.
- ^ Keiser J, Utzinger J. (2007). "Artemisinins and synthetic trioxolanes in the treatment of helminth infections.". Curr Opin Infect Dis. 20 (6): 605–612. doi:10.1097/QCO.0b013e3282f19ec4. PMID 17975411.
- ^ Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao S, Tanner M. (2000). "Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial.". Lancet 355 (9212): 1320–5. doi:10.1016/S0140-6736(00)02114-0. PMID 10776745. http://linkinghub.elsevier.com/retrieve/pii/S0140673600021140.
- ^ Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP. (2005). "A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China.". Acta Trop. 96 (23): 184–190. doi:10.1016/j.actatropica.2005.07.013. PMID 16112071.
- ^ a b Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM (December 2008). "Evidence of artemisinin-resistant malaria in western Cambodia". N. Engl. J. Med. 359 (24): 2619–20. doi:10.1056/NEJMc0805011. PMID 19064625.
- ^ a b Dondorp AM, Nosten F, Yi P, et al. (July 2009). "Artemisinin resistance in Plasmodium falciparum malaria". N. Engl. J. Med. 361 (5): 455–67. doi:10.1056/NEJMoa0808859. PMID 19641202.
- ^ Drugs immunity ‘may’ fail malaria fight. The Jakarta Post, April 23, 2011.
- ^ a b Taylor WR, White NJ (2004). "Antimalarial drug toxicity: a review". Drug Saf 27 (1): 25–61. doi:10.2165/00002018-200427010-00003. PMID 14720085.
- ^ Leonardi E, Gilvary G, White NJ, Nosten F (2001). "Severe allergic reactions to oral artesunate: a report of two cases". Trans. R. Soc. Trop. Med. Hyg. 95 (2): 182–3. doi:10.1016/S0035-9203(01)90157-9. PMID 11355556.
- ^ "Hepatitis Temporally Associated with an Herbal Supplement Containing Artemisinin — Washington, 2008". CDC. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5831a3.htm.
- ^ R. Price et al. (1999). "Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives". American Journal of Tropical Medicine and Hygiene 60 (4): 547–555. PMID 10348227. http://www.ajtmh.org/cgi/content/abstract/60/4/547.
- ^ Kappe SH, Vaughan AM, Boddey JA, Cowman AF (May 2010). "That was then but this is now: malaria research in the time of an eradication agenda". Science 328 (5980): 862–6. doi:10.1126/science.1184785. PMID 20466924.
- ^ S. Krishna et al. (2004). "Artemisinins: mechanisms of action and potential for resistance". Drug Resistance Updates 7: 233–244. doi:10.1016/j.drup.2004.07.001. http://archives.who.int/eml/expcom/children/Applications/REF8.pdf.
- ^ Cumming JN; Ploypradith P; Posner GH (1997). "Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action". Adv. Pharmacol. 37: 253–97. PMID 8891104.
- ^ Pandey AV, Tekwani BL, Singh RL, Chauhan VS (July 1999). "Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite". J. Biol. Chem. 274 (27): 19383–8. doi:10.1074/jbc.274.27.19383. PMID 10383451.
- ^ del Pilar Crespo M, Avery TD, Hanssen E, et al. (January 2008). "Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology". Antimicrob. Agents Chemother. 52 (1): 98–109. doi:10.1128/AAC.00609-07. PMC 2223901. PMID 17938190. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2223901.
- ^ Abu Bakar N, Klonis N, Hanssen E, Chan C, Tilley L (February 2010). "Digestive-vacuole genesis and endocytic processes in the early intraerythrocytic stages of Plasmodium falciparum". J. Cell. Sci. 123 (Pt 3): 441–50. doi:10.1242/jcs.061499. PMID 20067995.
- ^ Cardi D, Pozza A, Arnou B, et al. (June 2010). "Purified E255L mutant SERCA1a and purified PFATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins". J Biol Chem 285 (34): 26406–16. doi:10.1074/jbc.M109.090340. PMC 2924071. PMID 20530490. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2924071.
- ^ Arnou, B.; Montigny, C.; Morth, JP.; Nissen, P.; Jaxel, C.; Møller, JV.; Maire, M. (Jun 2011). "The Plasmodium falciparum Ca2+-ATPase PfATP6: insensitive to artemisinin, but a potential drug target.". Biochem Soc Trans 39 (3): 823–31. doi:10.1042/BST0390823. PMID 21599655.
- ^ Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S (June 2010). "Investigations into the Role of the Plasmodium falciparum SERCA (PfATP6) L263E Mutation in Artemisinin Action and Resistance". Antimicrob Agents Chemother 54 (9): 3842–52. doi:10.1128/AAC.00121-10. PMC 2935017. PMID 20566762. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2935017.
- ^ Jambou R, Legrand E, Niang M, et al. (December 2005). "Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6". Lancet 366 (9501): 1960–3. doi:10.1016/S0140-6736(05)67787-2. PMID 16325698. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)67787-2.
- ^ Shahinas D, Lau R, Khairnar K, Hancock D, Pillai DR (October 2010). "Artesunate misuse and Plasmodium falciparum malaria in traveler returning from Africa". Emerging Infect. Dis. 16 (10): 1608–10. PMID 20875291.
- ^ Li W, Mo W, Shen D, et al. (September 2005). "Yeast model uncovers dual roles of mitochondria in action of artemisinin". PLoS Genet. 1 (3): e36. doi:10.1371/journal.pgen.0010036. PMC 1201371. PMID 16170412. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1201371.
- ^ Vugt MV, Wilairatana P, Gemperli B, et al. (1999). "Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria". Am J Trop Med Hyg 60 (6): 936–42. PMID 10403324.
- ^ Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. (2001). "A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand". Am J Trop Med Hyg 64 (5-6): 247–56. PMID 11463111.
- ^ Mutabingwa TK, Anthony D, Heller A, et al. (2005). "Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial". Lancet 365 (9469): 1474–80. doi:10.1016/S0140-6736(05)66417-3. PMID 15850631.
- ^ Jansen FH (2006). "The herbal tea approach for artemesinin as a therapy for malaria?". Trans R Soc Trop Med Hyg 100 (3): 285–6. doi:10.1016/j.trstmh.2005.08.004. PMID 16274712.
- ^ RITAM Artemisia annua Task Force (2007). "Artemisia Annua as a herbal tea for malaria". Afr J Tradit Complement Altern Med 4 (1): 121–3. ISSN 0189-6016. PMC 2816434. PMID 20162081. http://www.bioline.org.br/request?tc07001.
- ^ a b "Report of the Artemisinin Enterprise Conference 2008". http://www.york.ac.uk/org/cnap/artemisiaproject/pdfs/AEconference-report-web.pdf.
- ^ Artemisinin combination therapies, CNAP Artemisia Project
- ^ Schmid G., Hofheinz W. (1983). "Total Synthesis of qinghaosu". J. Am. Chem. Soc. 105 (3): 624–5. doi:10.1021/ja00341a054.
- ^ Ro DK, Paradise EM, Ouellet M, et al. (April 2006). "Production of the antimalarial drug precursor artemisinic acid in engineered yeast". Nature 440 (7086): 940–3. doi:10.1038/nature04640. PMID 16612385.
- ^ Amyris Biotechnologies
- ^ "Press Release". Institute for One World Health. http://www.oneworldhealth.org/press_releases/view/pr_1305150097.
- ^ "World Malaria Report 2010, chapter 5". WHO. http://www.who.int/malaria/world_malaria_report_2010/en/index.html.
- ^ van Herpen, TW.; Cankar, K.; Nogueira, M.; Bosch, D.; Bouwmeester, HJ.; Beekwilder, J. (3 December 2010). "Nicotiana benthamiana as a production platform for artemisinin precursors.". PLoS One 5 (12): e14222. doi:10.1371/journal.pone.0014222. PMID 21151979.
- History, Aetiology, Pathophysiology, Clinical Features, Diagnosis, Treatment, Complications And Control Of Malaria: Artemisinin Derivatives
- Design and synthesis of antimalarial endoperoxides
- van Vugt M, Looareesuwan S, Wilairatana P, et al. (2000). "Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria". Trans. R. Soc. Trop. Med. Hyg. 94 (5): 545–8. doi:10.1016/S0035-9203(00)90082-8. PMID 11132386.
- Daviss B (2005). "Malaria, Science, and Social Responsibility: Nonprofit drug-development partnership seeks to cure the ills of developing nations". The Scientist 19 (6): 42. http://www.the-scientist.com/2005/3/28/42/1.
- Research on the use of artemisinin for cancer treatment
- Ferreira, J.F. (2004). "Artemisia Annua L.: the Hope Against Malaria and Cancer". Proceedings of the 2nd Annual Symposium, Appalachian Opportunities, Medicinal and Aromatic Plants: Production, Business & Applications. Mountain State University/USDA, ARS, Appalachian Farming Systems Research Center. pp. 56–61. http://www.ars.usda.gov/research/publications/Publications.htm?seq_no_115=168984.
- Artemisinin — Researchers blend folk treatment, high tech for promising anti-cancer compound
- BBC Horizon documentary about artemisinin
- Artemisinin: From Malaria to Cancer Treatment, by Robert Jay Rowen, MD Editor-in-Chief, Second Opinion
- Artemisia Annua, by Memorial-Sloan Kettering Cancer Center
- Use of Artemisinin for Cancer Treatment and Bacterial Infection, Henry Lai, Ph.D., University of Washington (streaming video, Spring 2005)
- Assured Artemisinin Supply System, support the global production of sufficient Artemisia/artemisinin to meet the expanded needs
- Artemisinin latest patents, covering use in fighting infections, including viral infections; fighting cancer; various novel derivatives and ACTs; high-yielding Artemisia plants; and extraction methods.
Antiparasitics – antiprotozoal agents – Chromalveolate antiparasitics (P01) Alveo-
(antifols)Sulfadoxine • sulfamethoxypyrazineCoformulationFansidar# (sulfadoxine/pyrimethamine)OtherCombi-
nationsFixed-dose (coformulated) ACTsOther combinations
(not co-formulated)artesunate/SP • artesunate/mefloquine •
quinine/tetracycline • quinine/doxycycline • quinine/clindamycin
Wikimedia Foundation. 2010.
Look at other dictionaries:
Artemisinin — Strukturformel Allgemeines Freiname Artemisinin Andere Namen … Deutsch Wikipedia
artemisinin — A sesquiterpene antimalarial and antischistosomal drug derived from Artemisia annua; a. is a potent and rapidly acting blood schizontocide that has been reported to be very useful in the treatment of cerebral malaria; active against chloroquine… … Medical dictionary
artemisinin — n. the active ingredient of qinghaosu, a Chinese herbal medicine prepared from a species of wormwood (Artemisia annua) and long used for treating malaria. Derivatives of artemisinin (including artesunate and artemether) have been developed for… … The new mediacal dictionary
artemisinin — noun an anti malarial drug derived from the wormwood shrub, found as the active ingredient in traditional Chinese medical herbal treatment for malaria, chemically a sesquiterpene lactone … Wiktionary
artemisinin — [ˌα:tɪ mi:sɪnɪn] noun a terpene based antimalarial substance obtained from an artemisia and used in Chinese medicine … English new terms dictionary
artemisinin — artemisˈinin noun see ↑qinghaosu • • • Main Entry: ↑artemisia … Useful english dictionary
Artemisinin-based Combination Treatment — Artémisinine Artémisinine Général No CAS 63968 64 9 … Wikipédia en Français
History of malaria — The history of malaria predates humanity, as this ancient disease evolved before humans did. Malaria, a widespread and potentially lethal infectious disease, has afflicted people for much of human history, and has affected settlement patterns.… … Wikipedia
Artemisin — Strukturformel Allgemeines Name Artemisinin Andere Namen (3R,5aS,6R,8aS,9R,12S,12aR) Octahydro 3,6 … Deutsch Wikipedia
Tu Youyou — (chinesisch 屠呦呦 Tú Yōuyōu; * 12. Dezember 1930 in Ningbo) ist eine chinesische Pharmakologin. Sie isolierte den zur Behandlung der Malaria eingesetzten sekundären Pflanzenstoff Artemisinin aus dem Einjährigen Beifuß (Artemisia… … Deutsch Wikipedia